PBAC's latest decision on Prednisolone with phenylephrine: Recommended with restriction (2019). Considered for Treatment of severe eye inflammation following cataract surgery for patients who identify as Aboriginal or Torres Strait Islander.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Aboriginal and Torres Strait Islander patients who have had or are scheduled for cataract surgery requiring post-operative anti-inflammatory treatment.
Therapy area
Ophthalmology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
dexamethasone and fluorometholone
Economic model
Cost-minimisation
Eligible patients/year
1,711
ICER note
not-modelled — this is a minor submission (price/population extension of existing listing) with cost-minimisation analysis only; no ICER calculated